Patients Harboring ALK Rearrangement Adenocarcinoma after Acquired Resistance to Crizotinib and Transformation to SCLC: A Case Report

被引：0
|
作者：
Wang, W. [1 ]
Xu, C. [2 ]
Zhu, Y. [3 ]
Liao, X. [4 ]
Zhuang, W. [5 ]
Du, K. [3 ]
Chen, R. [6 ]
Chen, Y. [2 ]
Chen, G. [2 ]
Fang, M. [1 ]
机构：
[1] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[2] Fujian Prov Canc Hosp, Pathol, Fuzhou, Fujian, Peoples R China
[3] Zhejiang Rongjun Hosp, Chest Dis Diag & Treatment Ctr, Jiaxing, Peoples R China
[4] Zhejiang Rongjun Hosp, Tumor Mol Lab, Jiaxing, Peoples R China
[5] Fujian Prov Canc Hosp, Med Oncol, Fuzhou, Fujian, Peoples R China
[6] Geneplus Beijing, Beijing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
crizotinib; Resistance; small-cell lung cancer;
D O I：
10.1016/j.jtho.2017.09.1548
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.02-018
引用
收藏
页码：S2244 / S2244
页数：1
相关论文
共 50 条
  • [1] Patients harboring ALK rearrangement adenocarcinoma after acquired resistance to crizotinib and transformation to small-cell lung cancer: a case report
    Zhu, You-cai
    Liao, Xing-hui
    Wang, Wen-xian
    Xu, Chun-wei
    Zhuang, Wu
    Zhong, Li-hua
    Du, Kai-qi
    Chen, Yan-ping
    Chen, Gang
    Fang, Mei-yu
    ONCOTARGETS AND THERAPY, 2017, 10 : 3187 - 3192
  • [2] ALK-Positive Adenocarcinoma After Acquired Resistance to Lorlatinib and Transformation to SCLC: A Case Report
    Li, Huihui
    Song, Tianqi
    Xu, Xiaoling
    JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02):
  • [3] Patients Harboring a Novel PIK3CA Point Mutation after Acquired Resistance to Crizotinib in ROS1 Rearrangement Adenocarcinoma: A Case Report
    Fang, M.
    Wang, W.
    Xu, C.
    Liu, R.
    Liao, X.
    Zhu, Y.
    Du, K.
    Zhuang, W.
    Chen, Y.
    Chen, G.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1892 - S1893
  • [4] SCLC Transformation from ALK-rearranged Lung Adenocarcinoma after Alectinib Resistance and Response to Atezolizumab: Case Report
    Xia, G.
    Yu, S.
    Ni, J.
    Song, M.
    Zhang, J.
    Huang, M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S526 - S527
  • [5] Lung adenocarcinoma with concurrent KRAS mutation and ALK rearrangement responding to crizotinib: case report
    Campos-Gomez, Saul
    Lara-Guerra, Humberto
    Routbort, Mark J.
    Lu, Xinyan
    Simon, George R.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2015, 30 (02): : E254 - E257
  • [6] Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: A case report and literature review
    Xu, Chun-wei
    Wang, Wen-xian
    Huang, Rong-fang
    He, Cheng
    Liao, Xing-hui
    Zhu, You-cai
    Du, Kai-qi
    Zhuang, Wu
    Chen, Yan-ping
    Chen, Gang
    Fang, Mei-yu
    THORACIC CANCER, 2017, 8 (06) : 714 - 719
  • [7] A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4-ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib
    Omachi, Naoki
    Shimizu, Shigeki
    Kawaguchi, Tomoya
    Tezuka, Kenji
    Kanazu, Masaki
    Tamiya, Akihiro
    Asami, Kazuhiro
    Okishio, Kyoichi
    Kitaichi, Masanori
    Atagi, Shinji
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (06) : E40 - E42
  • [8] Clinical activity of crizotinib in lung adenocarcinoma harboring a HLA_A-ROS1 rearrangement: A case report
    Kinoshita, Ryosuke
    Nakao, Makoto
    Kiyotoshi, Hiroko
    Hayashi, Syuntaro
    Sugihara, Masahiro
    Hirata, Yuya
    Kuriyama, Mamiko
    Takeda, Norihisa
    Muramatsu, Hideki
    ONCOLOGY LETTERS, 2023, 26 (06)
  • [9] Transformation of ALK-positive NSCLC to SCLC after alectinib resistance and response to combined atezolizumab: a case report
    Xia, Guohao
    Huang, Jiayuan
    Ni, Jie
    Song, Meng
    Zhang, Junling
    Hofman, Paul
    Christopoulos, Petros
    Grenda, Anna
    Huang, Mengli
    TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (03) : 637 - 646
  • [10] A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib
    Cha, Yoon Jin
    Cho, Byoung Chul
    Kim, Hye Ryun
    Lee, Hye-Jeong
    Shim, Hyo Sup
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (05) : E55 - E58
12345